Structure of compound 23

selective oral serine protease FXia inhibitor

projected BID dosing in patients

from 1.8k cmpd protease inh. screen + SBDD

J. Med. Chem., Jun. 17, 2020

Novartis (NIBR), Basel, Switzerland

“compound 23” is an oral, selective Factor XIa inhibitor intended as an anticoagulation agent. Since the clinical translatability of FXIa inhibition in preclinical models hasn’t been established, this program was…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.